Press Release European Medicines Agency Validates BioMarin’s Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Press Release BioMarin Announces Pricing of Concurrent Public Offerings of 9,000,000 Shares of Common Stock and $150 Million Senior Subordinated Convertible Notes
Press Release BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024
Press Release BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET
Press Release BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET
Press Release BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
